Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phentermine resin is an extended-release formulation of phentermine, a sympathomimetic amine anorectic. It is prescribed for the short-term management of exogenous obesity as an adjunct to a comprehensive weight reduction program involving exercise, behavioral modification, and caloric restriction. The drug functions as a central nervous system stimulant, primarily by promoting the release of norepinephrine and dopamine, and to a lesser extent, serotonin, which leads to appetite suppression and increased satiety. Additionally, it may inhibit neuropeptide Y, a key pathway for hunger induction. Phentermine resin is a Schedule IV controlled substance due to its potential for abuse and dependence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phentermine resin.